Healthcare Sales & Marketing Network News: giant cell tumor of bone

Searching News Database: giant cell tumor of bone

HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Jun 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jun 2013
FDA Approves Amgen's XGEVA(R) (denosumab) For The Treatment Of Giant Cell Tumor Of Bone
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 May 2008
Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate
Biopharmaceuticals Oncology

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.